Aspira Pathlab & Diagnostics Ltd

Aspira Pathlab & Diagnostics Ltd has announced the resignation of M/s. Vishal J Bhanushali and Associates from their position as Internal Auditor. The resignation is effective from August 13, 2026, and is attributed to preoccupation and other personal reasons. The company has provided the necessary disclosures as per SEBI LODR regulations. The firm expressed gratitude to the outgoing auditor for their service.

Aspira Pathlab & Diagnostics Ltd announced the resignation of Mr. Pankaj Jashwant Shah from his positions as Managing Director and Chief Executive Officer. The resignation is effective from August 3, 2026, and is due to personal reasons. Mr. Shah has expressed gratitude to the Board and Management for their support during his tenure. The company will take necessary steps as per applicable laws.

Aspira Pathlab & Diagnostics Ltd announced the resignation of Mr. Pankaj Jashwant Shah from his positions as Managing Director and Chief Executive Officer, effective August 3, 2026. The resignation is attributed to personal reasons. Mr. Shah has expressed gratitude to the Board for the support during his tenure. The company will take necessary steps as per applicable laws.

Aspira Pathlab & Diagnostics Ltd announced the resignation of Pankaj Jashwant Shah from his positions as Managing Director and Chief Executive Director, effective August 3, 2026. The resignation is due to personal reasons. The company has provided the necessary disclosures as per SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Aspira Pathlab & Diagnostics Ltd announced the resignation of Mr. Vaibhav Odhekar as an Additional Executive Director. The resignation is effective from the close of business hours on July 25, 2026, and is due to personal reasons. The company has provided the necessary disclosures as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Odhekar expressed gratitude for the opportunity and support during his tenure.

Mr. Vaibhav Odhekar has resigned as Additional Executive Director of Aspira Pathlab & Diagnostics Ltd. The resignation is effective from the close of business hours on July 25, 2026. The company cited personal reasons for his departure. Mr. Odhekar expressed gratitude to the Board and Management for their support during his tenure.

Aspira Pathlab & Diagnostics Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is effective from July 1, 2026, and will continue until the declaration of the unaudited standalone financial results for the quarter ended June 30, 2026, plus 48 hours thereafter. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct, aimed at preventing insider trading during the sensitive period of financial reporting.

Aspira Pathlab & Diagnostics Ltd has announced the classification of Mr. Nikunj Mange and Mr. Jay Arvind Bhanushali as Promoters of the company. This change follows the successful completion of an Open Offer made under SEBI regulations. Mr. Mange, previously a Director, is now a Promoter, and Mr. Bhanushali, who was not a Promoter before, also attains this status. The reclassification is effective immediately upon the Open Offer's conclusion, adhering to SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Shraddha Bhanushali and Persons Acting in Concert (PACs) have filed a disclosure under SEBI's SAST Regulations, 2011, regarding their shareholding in Aspira Pathlab & Diagnostics Ltd. The filing details the acquisition of 22,82,507 shares, representing 22.18% of the total voting capital. This disclosure is a routine regulatory requirement for substantial changes in shareholding.

Deepali Arvind Bhanushali and Persons Acting in Concert (PACs) have acquired 85,443 equity shares, representing 0.83% of the total share capital, of Aspira Pathlab & Diagnostics Ltd through an open offer. Following this acquisition, their combined holding has increased. The total number of equity shares acquired in the open offer by all acquirers amounts to 22,82,507 shares, constituting 22.18% of the total equity.